Ar­ray MEK/BRAF com­bo beats out Roche ri­val in PhI­II melanoma OS show­down

Ar­ray Bio­Phar­ma’s MEK/BRAF in­hibitor com­bo hand­i­ly beat out Roche’s Zelb­o­raf on over­all sur­vival scores among a group of pa­tients suf­fer­ing from ad­vanced melanoma with a BRAF mu­ta­tion.

Al­ready up for re­view at the FDA af­ter post­ing pos­i­tive pro­gres­sion-free sur­vival da­ta, the Boul­der, CO-based com­pa­ny re­port­ed to­day that the com­bi­na­tion of en­co­rafenib 450 mg dai­ly and binime­tinib 45 mg twice dai­ly — dubbed COM­BO450 — pro­duced a me­di­an OS of 33.6 months, dou­bling the 16.9 months record­ed in the Zelb­o­raf (ve­mu­rafinib) arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER